UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Atazanavir Plus Cobicistat: Week 48 and Week 144 Subgroup Analyses of a Phase 3, Randomized, Double-Blind, Active-Controlled Trial

Current HIV research, 2017-01, Vol.15 (3), p.216

2017

Volltextzugriff (PDF)

Implementation of a community pharmacy-based pre-exposure prophylaxis service: a novel model for pre-exposure prophylaxis care

Sexual health, 2018-01, Vol.15 (6), p.556

2018

Volltextzugriff (PDF)

Management of dyslipidemia in patients with human immunodeficiency virus

Reviews in cardiovascular medicine, 2014, Vol.15 Suppl 1, p.S38

Shalit, Peter

2014

Volltextzugriff (PDF)

Loneliness among older adults living with HIV: the "older old" may be less lonely than the "younger old"

AIDS care, 2021-03, Vol.33 (3), p.375-382

2021

Volltextzugriff (PDF)

Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate in the First Protease Inhibitor-Based Single-Tablet Regimen for Initial HIV-1 Therapy: A Randomized Phase 2 Study

Journal of acquired immune deficiency syndromes (1999), 2015-08, Vol.69 (4), p.439-445

2015

Volltextzugriff (PDF)

The TLR7 agonist vesatolimod induced a modest delay in viral rebound in HIV controllers after cessation of antiretroviral therapy

Science translational medicine, 2021-06, Vol.13 (599)

2021

Volltextzugriff (PDF)

HIV rebound in HIV controllers is associated with a specific fecal microbiome profile

European journal of immunology, 2024-08, Vol.54 (8), p.e2350809-n/a

2024

Volltextzugriff (PDF)

Phase 2 study of cobicistat versus ritonavir each with once-daily atazanavir and fixed-dose emtricitabine/ tenofovir df in the initial treatment of HIV infection

AIDS (London), 2011-09, Vol.25 (15), p.1881-1886

2011

Volltextzugriff (PDF)

1570. Exploring Antiretroviral Therapy (ART) Switch Decisions in Clinical Setting: Trio Health Mixed Methods Study

Open forum infectious diseases, 2023-11, Vol.10 (Supplement_2)

2023

Volltextzugriff (PDF)

872. Number of Sexual Partners and Patient-Reported Outcomes among Older Adults Living With HIV

Open forum infectious diseases, 2021-12, Vol.8 (Supplement_1), p.S527-S528

2021

Volltextzugriff (PDF)

Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial

The lancet HIV, 2021-07, Vol.8 (7), p.e397-e407

2021

Volltextzugriff (PDF)

Prescribing and using self-injectable antiretrovirals: how concordant are physician and patient perspectives?

AIDS research and therapy, 2009-02, Vol.6 (1), p.2-2

2009

Volltextzugriff (PDF)

854. Long-term Outcomes of Participants on F/TAF for Pre-Exposure Prophylaxis: Results for 144 Weeks of Follow-Up in the DISCOVER Trial

Open forum infectious diseases, 2021-12, Vol.8 (Supplement_1), p.S517-S518

2021

Volltextzugriff (PDF)

Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomized trial

AIDS (London), 2010-01, Vol.24 (1), p.55-65

2010

Volltextzugriff (PDF)

605. Loneliness Among Older Adults Living with HIV: A Study and Online Community

Open forum infectious diseases, 2018-11, Vol.5 (suppl_1), p.S221-S221

2018

Volltextzugriff (PDF)

Improvement in Lipoatrophy Associated with Highly Active Antiretroviral Therapy in Human Immunodeficiency Virus—Infected Patients Switched from Stavudine to Abacavir or Zidovudine: The Results of the TARHEEL Study

Clinical infectious diseases, 2004-01, Vol.38 (2), p.263-270

2004

Volltextzugriff (PDF)

1905. Real-World Insights into Quality Improvement across 11 HIV Clinics in the United States

Open forum infectious diseases, 2018-11, Vol.5 (suppl_1), p.S547-S548

2018

Volltextzugriff (PDF)

Long-term efficacy, safety, and tolerability of rilpivirine (RPV, TMC278) in HIV type 1-infected antiretroviral-naive patients: week 192 results from a phase IIb randomized trial

AIDS research and human retroviruses, 2012-05, Vol.28 (5), p.437-446

2012

Volltextzugriff (PDF)

The Intelence aNd pRezista Once A Day Study (INROADS): a multicentre, single‐arm, open‐label study of etravirine and darunavir/ritonavir as dual therapy in HIV‐1‐infected early treatment‐experienced subjects

HIV medicine, 2015-05, Vol.16 (5), p.288-296

2015

Volltextzugriff (PDF)

1962. Renal Outcomes for Participants Taking F/TAF vs. F/TDF for HIV PrEP in the DISCOVER Trial

Open forum infectious diseases, 2019-10, Vol.6 (Supplement_2), p.S64-S64

2019

Volltextzugriff (PDF)

Efficacy and safety of etravirine (TMC125) in patients with highly resistant HIV-1 : primary 24-week analysis

AIDS (London), 2007-03, Vol.21 (6), p.F1-F10

2007

Volltextzugriff (PDF)

Patient-Reported Outcomes After a Switch to a Single-Tablet Regimen of Rilpivirine, Emtricitabine, and Tenofovir DF in HIV-1-Positive, Virologically Suppressed Individuals: Additional Findings From a Randomized, Open-Label, 48-Week Trial

The patient : patient-centered outcomes research, 2015-06, Vol.8 (3), p.257-267

2015

Volltextzugriff (PDF)

Efficacy and Safety of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate in Human Immunodeficiency Virus (HIV)-Infected, Virologically Suppressed Older Adults: Subgroup Analysis of a Randomized, Double-Blind Switch Study

Open forum infectious diseases, 2016-12, Vol.3 (suppl_1)

2016

Volltextzugriff (PDF)

Atazanavir Plus Cobicistat (ATV + c) Versus Atazanavir Plus Ritonavir (ATV + r), Both in Combination With Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF): Week 48 Subgroup Analysis of a Phase 3, Randomized, Double-Blind, Active-Controlled Trial

Open forum infectious diseases, 2015-12, Vol.2 (suppl_1)

2015

Volltextzugriff (PDF)

906Atazanavir Plus Cobicistat (ATV + c) Versus Atazanavir Plus Ritonavir (ATV + r), Both in Combination With Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF): Week 48 Subgroup Analysis of a Phase 3, Randomized, Double-Blind, Active-Controlled Trial

Open forum infectious diseases, 2015-12, Vol.2 (suppl_1), p.S265-S266

2015

Volltextzugriff (PDF)

1 – 25 von 69

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(59)
Mit Volltextzugriff
(50)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Englisch
(69)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Atazanavir Plus Cobicistat: Week 48 and Week 144 Subgroup Analyses of a Phase 3, Randomized, Double-Blind, Active-Controlled Trial

Implementation of a community pharmacy-based pre-exposure prophylaxis service: a novel model for pre-exposure prophylaxis care

Management of dyslipidemia in patients with human immunodeficiency virus

Loneliness among older adults living with HIV: the "older old" may be less lonely than the "younger old"

Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate in the First Protease Inhibitor-Based Single-Tablet Regimen for Initial HIV-1 Therapy: A Randomized Phase 2 Study

The TLR7 agonist vesatolimod induced a modest delay in viral rebound in HIV controllers after cessation of antiretroviral therapy

HIV rebound in HIV controllers is associated with a specific fecal microbiome profile

Phase 2 study of cobicistat versus ritonavir each with once-daily atazanavir and fixed-dose emtricitabine/ tenofovir df in the initial treatment of HIV infection

1570. Exploring Antiretroviral Therapy (ART) Switch Decisions in Clinical Setting: Trio Health Mixed Methods Study

872. Number of Sexual Partners and Patient-Reported Outcomes among Older Adults Living With HIV

Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial

Prescribing and using self-injectable antiretrovirals: how concordant are physician and patient perspectives?

854. Long-term Outcomes of Participants on F/TAF for Pre-Exposure Prophylaxis: Results for 144 Weeks of Follow-Up in the DISCOVER Trial

Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomized trial

605. Loneliness Among Older Adults Living with HIV: A Study and Online Community

Improvement in Lipoatrophy Associated with Highly Active Antiretroviral Therapy in Human Immunodeficiency Virus—Infected Patients Switched from Stavudine to Abacavir or Zidovudine: The Results of the TARHEEL Study

1905. Real-World Insights into Quality Improvement across 11 HIV Clinics in the United States

Long-term efficacy, safety, and tolerability of rilpivirine (RPV, TMC278) in HIV type 1-infected antiretroviral-naive patients: week 192 results from a phase IIb randomized trial

The Intelence aNd pRezista Once A Day Study (INROADS): a multicentre, single‐arm, open‐label study of etravirine and darunavir/ritonavir as dual therapy in HIV‐1‐infected early treatment‐experienced subjects

1962. Renal Outcomes for Participants Taking F/TAF vs. F/TDF for HIV PrEP in the DISCOVER Trial

Efficacy and safety of etravirine (TMC125) in patients with highly resistant HIV-1 : primary 24-week analysis

Patient-Reported Outcomes After a Switch to a Single-Tablet Regimen of Rilpivirine, Emtricitabine, and Tenofovir DF in HIV-1-Positive, Virologically Suppressed Individuals: Additional Findings From a Randomized, Open-Label, 48-Week Trial

Efficacy and Safety of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate in Human Immunodeficiency Virus (HIV)-Infected, Virologically Suppressed Older Adults: Subgroup Analysis of a Randomized, Double-Blind Switch Study

Atazanavir Plus Cobicistat (ATV + c) Versus Atazanavir Plus Ritonavir (ATV + r), Both in Combination With Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF): Week 48 Subgroup Analysis of a Phase 3, Randomized, Double-Blind, Active-Controlled Trial

906Atazanavir Plus Cobicistat (ATV + c) Versus Atazanavir Plus Ritonavir (ATV + r), Both in Combination With Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF): Week 48 Subgroup Analysis of a Phase 3, Randomized, Double-Blind, Active-Controlled Trial

Suchergebnisse filtern